CTOs on the Move


 
Indiva is a Canadian licensed producer of premium cannabis and cannabis products, and a provider of extraction, manufacturing and refinement services.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.indiva.com
  • 1050 Hargrieve Drive Unit 10
    London, ON CAN N6E 1P5
  • Phone: N/A

Executives

Name Title Contact Details

Funding

Indiva raised $14M on 10/16/2019
Indiva raised $11M on 02/16/2021

Similar Companies

Sparrow Pharmaceuticals

Sparrow Pharmaceuticals is developing targeted therapies for conditions of corticosteroid excess - associated with either the natural corticosteroid cortisol due to a tumor or long-term use of a corticosteroid drug such as prednisone. Sparrow`s pipeline is led by SPI-62 in Phase 2 clinical development.

Glenmark Generics Limited

Glenmark Generics Limited is a Mahwah, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Radioisotope Life Sciences

RLS (Radioisotope Life Sciences), the third-largest nuclear medicine pharmacy network in the United States, owns and operates 31 radiopharmacies across 18 states, offering an extensive portfolio of molecular imaging products. We endeavor to supply the highest quality radiopharmaceuticals in the industry by dispensing 100 percent of injectable unit dose products in clean rooms built to ISO 1644-1 specifications. In support of our commitment to quality, we provide tailored solutions and exceptional service to our more than 1500 customers.

PharmaLink

PharmaLink is a Largo, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ophthotech

Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat back of the eye diseases, with a focus on developing innovative therapies for age-related macular degeneration (AMD). Ophthotech`s most advanced product candidate, Fovista® anti-PDGF therapy, is in Phase 3 clinical trials for use in combination with anti-VEGF therapy that represents the current standard of care for the treatment of wet AMD. Ophthotech`s second product candidate, Zimura®, an inhibitor of complement factor C5, is being developed for the treatment of geographic atrophy, a form of dry AMD.